review on glp-1 agonists and psychiatric effects Glucagon-like peptide-1 medicines in neurological disorders Prospects of GLP-1 Therapies for

Alzheimers disease (AD) is the most common type of dementia

Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al

1 Population size

Tackle things that you never did before that you maybe can now start to do, to increase your motivation and enjoy your new life and your healthier body

Chen Z, Liu XA, Kenny PJ

OM reports grant for advisory board, speakers bureau, through Hadassah University Hospital, medical writing, support for travel, article processing charges from Novo Nordisk, a grant through Hadassah University Hospital from AstraZeneca, speakers bureau from Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca, and BOL Pharma, support for travel/meetings from AstraZeneca, and advisory board from Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, and BOL Pharma